MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-27-2025
Can-Fite BioPharma Ltd. Retained Earnings 2011-2026 | CANF
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Can-Fite BioPharma Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -166 M | -158 M | -151 M | -141 M | -125 M | -110 M | -101 M | -106 M | -91 M | -82.7 M | -78.1 M | -80.5 M | -67.3 M | -60.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -60.8 M | -166 M | -108 M |
Quarterly Retained Earnings Can-Fite BioPharma Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -141 M | - | -131 M | - | -125 M | - | -119 M | - | -110 M | - | - | - | -97.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -97.7 M | -141 M | -121 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.1 | 1.31 % | $ 7.46 B |  Australia |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.09 | -2.25 % | $ 5.94 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.95 | -1.27 % | $ 498 M | Britain |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 212.41 | 1.48 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.14 | 0.49 % | $ 1.68 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 94.97 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 26.71 | -1.07 % | $ 1.29 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.6 | 0.52 % | $ 141 M | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 570.58 | -0.27 % | $ 43.2 B | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 11.67 | 0.56 % | $ 768 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 92.13 | -0.41 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
ChromaDex Corporation
CDXC
|
-182 M | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 11.36 | -2.41 % | $ 735 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 176.12 | -0.16 % | $ 25.6 B | USA |
 |
Certara
CERT
|
-128 M | $ 8.78 | -0.9 % | $ 1.41 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-1.4 B | - | - | $ 7.29 B | USA |